CCL2 and congenital rubella syndrome: Neurotoxicity and CRS development after CAR-T therapy are directly related to in vivo T-cell expansion and subsequent secretion of T-cell effector cytokines such as IL-6, IFN-γ, GM-CSF, and MCP-1 suggesting that even monocytes and macrophages may have contributions in the emergence of such adverse events (15, 79–82).